A Brawl Is Brewing Between AbbVie and Gilead Sciences in Arthritis

There are more than 23 million people worldwide with rheumatoid arthritis, and despite current treatments, many patients fail to achieve disease remission or significant reductions in disease activity. The size of the addressable market and need for new drugs have made this indication a focus of drug development and new therapies from AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD) that work similarly are fast-approaching the Food and Drug Administration's finish line.